Novartis and BenevolentAI sign AI oncology deal

Swiss pharmaceutical company Novartis has united with BenevolentAI to aid in the discovery and development of new treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Bayer begins $240m AI drug discovery project with Exscientia

10 January 2020 Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

Asia

Insilico Medicine signs $200m AI drug discovery deal

10 October 2019 Hong Kong-based Insilico Medicine has agreed an artificial intelligence breast cancer drug discovery partnership worth a potential $200 million with a Chinese pharmaceutical company.

Big Pharma

AstraZeneca partners on AI drug discovery collaboration

2 May 2019 AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Novartis and BenevolentAI sign AI oncology deal

More on this story

Editor's picks

Editor's picks

More features